Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CU1N | ISIN: US90466Y1038 | Ticker-Symbol:
NASDAQ
14.11.24
19:33 Uhr
0,431 US-Dollar
-0,041
-8,62 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
UNICYCIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
UNICYCIVE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur UNICYCIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiUnicycive Therapeutics GAAP EPS of -$0.053
MiUnicycive Therapeutics, Inc.: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update57- OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025- - Commercial Planning in Progress for 2025 Launch - - Late Breaker Poster Presentation...
► Artikel lesen
UNICYCIVE THERAPEUTICS Aktie jetzt für 0€ handeln
MiUnicycive Therapeutics, Inc. - 8-K, Current Report-
MiUnicycive Therapeutics, Inc. - 10-Q, Quarterly Report1
MoUnicycive eyes June FDA verdict for hyperphosphataemia drug1
MoUnicycive Says FDA Accepts NDA For Oxylanthanum Carbonate To Treat Patients With CKD On Dialysis3
MoUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients ...57- FDA sets PDUFA Action Date of June 28, 2025 - Company Preparing for 2025 Commercial Launch - LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage...
► Artikel lesen
28.10.Unicycive Therapeutics, Inc.: Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology ...61- Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC - - Two Publications Recently Issued Featuring OLC and UNI-494 - LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE...
► Artikel lesen
16.10.Unicycive Therapeutics, Inc.: Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 20242
14.10.Unicycive to present kidney disease therapies at ASN Kidney Week2
14.10.Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 20241
10.10.Unicycive shares steady on positive Phase 1 study results2
09.10.Unicycive reports successful phase 1 kidney drug trial3
09.10.Unicycive Therapeutics, Inc.: Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers68LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
► Artikel lesen
25.09.Unicycive Therapeutics, Inc. - 8-K, Current Report5
24.09.Unicycive Therapeutics, Inc.: Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 20242
16.09.Unicycive Therapeutics, Inc.: Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 202422
05.09.Unicycive Therapeutics, Inc.: Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference2
03.09.Unicycive seeks FDA approval for kidney disease drug3
03.09.Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis92LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
► Artikel lesen
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1